TipRanks
Quoin Pharmaceuticals (DE:2EB0)
FRANKFURT:2EB0
Germany Market
2EB0
Quoin Pharmaceuticals
RESEARCH TOOLSreports

Quoin Pharmaceuticals (2EB0) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

2EB0 Analyst Ratings

Moderate Buy
2Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
Based on 2 analysts giving stock ratings to
Quoin
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

2EB0 Stock 12 Month Forecast

Average Price Target

€23.63
▲(402.66% Upside)
Based on 2 Wall Street analysts offering 12 month price targets for Quoin Pharmaceuticals in the last 3 months. The average price target is €23.63 with a high forecast of €30.07 and a low forecast of €17.18. The average price target represents a 402.66% change from the last price of €4.70.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","31":"€31","9.25":"€9.25","16.5":"€16.5","23.75":"€23.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30.06841845,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€30.07</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.625185925,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€23.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.1819534,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€17.18</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,9.25,16.5,23.75,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.7,6.651416803846154,8.602833607692308,10.554250411538462,12.505667215384616,14.45708401923077,16.408500823076924,18.359917626923078,20.311334430769232,22.262751234615383,24.214168038461537,26.16558484230769,28.117001646153845,{"y":30.06841845,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.7,6.155783532692308,7.611567065384616,9.067350598076924,10.523134130769233,11.97891766346154,13.434701196153846,14.890484728846154,16.346268261538462,17.80205179423077,19.25783532692308,20.713618859615387,22.169402392307692,{"y":23.625185925,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.7,5.660150261538462,6.620300523076923,7.580450784615385,8.540601046153848,9.500751307692308,10.46090156923077,11.421051830769233,12.381202092307694,13.341352353846155,14.301502615384617,15.26165287692308,16.221803138461542,{"y":17.1819534,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.36,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.92,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.66,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.35,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.75,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.08,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.88,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.1,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.96,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.86,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.58,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.7,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€30.07Average Price Target€23.63Lowest Price Target€17.18
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Maxim Group Analyst forecast on DE:2EB0
Naz Rahman
Maxim Group
Maxim Group
€13.75→€17.18
Buy
265.57%
Upside
Reiterated
09/03/26
Analysts' Top Healthcare Picks: Dogwood Therapeutics (DWTX), Quoin Pharmaceuticals (QNRX)
Alliance Global Partners Analyst forecast on DE:2EB0
James Molloy
Alliance Global Partners
Alliance Global Partners
€30.07
Buy
539.75%
Upside
Reiterated
08/17/26
Analysts Offer Insights on Healthcare Companies: Quoin Pharmaceuticals (NASDAQ: QNRX) and Pliant Therapeutics (NASDAQ: PLRX)
ThinkEquity Analyst forecast on DE:2EB0
Ashok Kumar
ThinkEquity
ThinkEquity
€10.31
Buy
119.34%
Upside
Initiated
06/15/26
Quoin Pharmaceuticals initiated with a Buy at ThinkEquityQuoin Pharmaceuticals initiated with a Buy at ThinkEquity
Lucid Capital Analyst forecast on DE:2EB0
Dev Prasad
Lucid Capital
Lucid Capital
€25.77
Buy
448.36%
Upside
Initiated
05/04/26
Quoin Pharmaceuticals initiated with a Buy at Lucid CapitalQuoin Pharmaceuticals initiated with a Buy at Lucid Capital
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Maxim Group Analyst forecast on DE:2EB0
Naz Rahman
Maxim Group
Maxim Group
€13.75→€17.18
Buy
265.57%
Upside
Reiterated
09/03/26
Analysts' Top Healthcare Picks: Dogwood Therapeutics (DWTX), Quoin Pharmaceuticals (QNRX)
Alliance Global Partners Analyst forecast on DE:2EB0
James Molloy
Alliance Global Partners
Alliance Global Partners
€30.07
Buy
539.75%
Upside
Reiterated
08/17/26
Analysts Offer Insights on Healthcare Companies: Quoin Pharmaceuticals (NASDAQ: QNRX) and Pliant Therapeutics (NASDAQ: PLRX)
ThinkEquity Analyst forecast on DE:2EB0
Ashok Kumar
ThinkEquity
ThinkEquity
€10.31
Buy
119.34%
Upside
Initiated
06/15/26
Quoin Pharmaceuticals initiated with a Buy at ThinkEquityQuoin Pharmaceuticals initiated with a Buy at ThinkEquity
Lucid Capital Analyst forecast on DE:2EB0
Dev Prasad
Lucid Capital
Lucid Capital
€25.77
Buy
448.36%
Upside
Initiated
05/04/26
Quoin Pharmaceuticals initiated with a Buy at Lucid CapitalQuoin Pharmaceuticals initiated with a Buy at Lucid Capital
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ARWRArrowhead Pharmaceuticals
ZYMEZymeworks
TEVATeva Pharmaceutical
AHCOAdaptHealth
PTGXProtagonist Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Quoin Pharmaceuticals

3 Months
Naz RahmanMaxim Group
Success Rate
5/30 ratings generated profit
17%
Average Return
-24.21%
Copying Naz Rahman's trades and holding each position for 3 Months would result in 16.67% of your transactions generating a profit, with an average return of -24.21% per trade.
1 Year
Naz RahmanMaxim Group
Success Rate
3/30 ratings generated profit
10%
Average Return
-50.66%
Copying Naz Rahman's trades and holding each position for 1 Year would result in 10.00% of your transactions generating a profit, with an average return of -50.66% per trade.
2 Years
Naz RahmanMaxim Group
Success Rate
4/30 ratings generated profit
13%
Average Return
-55.95%
Copying Naz Rahman's trades and holding each position for 2 Years would result in 13.33% of your transactions generating a profit, with an average return of -55.95% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2EB0 Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
6
5
6
4
3
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
5
6
4
3
In the current month, 2EB0 has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 2EB0 average Analyst price target in the past 3 months is 23.63.
Each month's total comprises the sum of three months' worth of ratings.

2EB0 Financial Forecast

2EB0 Earnings Forecast

Next quarter’s earnings estimate for 2EB0 is -€1.41 with a range of -€1.77 to -€0.97. The previous quarter’s EPS was -€1.64. 2EB0 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 2EB0 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 2EB0 is -€1.41 with a range of -€1.77 to -€0.97. The previous quarter’s EPS was -€1.64. 2EB0 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 2EB0 has Performed in-line its overall industry.
No data currently available

2EB0 Sales Forecast

Next quarter’s sales forecast for 2EB0 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 2EB0 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 2EB0 has Performed in-line its overall industry.
Next quarter’s sales forecast for 2EB0 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 2EB0 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 2EB0 has Performed in-line its overall industry.

2EB0 Stock Forecast FAQ

What is DE:2EB0’s average 12-month price target, according to analysts?
Based on analyst ratings, Quoin Pharmaceuticals’s 12-month average price target is 23.63.
    What is DE:2EB0’s upside potential, based on the analysts’ average price target?
    Quoin Pharmaceuticals has 402.66% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Quoin Pharmaceuticals a Buy, Sell or Hold?
          Quoin Pharmaceuticals has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Quoin Pharmaceuticals’s share price target?
            The average share price target for Quoin Pharmaceuticals is 23.63. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €30.07 ,and the lowest forecast is €17.18. The average share price target represents 402.66% Increase from the current price of €4.7.
              What do analysts say about Quoin Pharmaceuticals?
              Quoin Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
                How can I buy shares of Quoin Pharmaceuticals?
                To buy shares of DE:2EB0, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.